Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 9, 2016
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
Atul A Deodhar, Maxime Dougados, Dominique L Baeten, et al.
European Journal of Rheumatology
|
November 3, 2018
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
Walter P Maksymowych, Vibeke Strand, Peter Nash, et al.
Arthritis Care & Research
|
November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
Tore K Kvien, Philip G Conaghan, Laure Gossec, et al.
Annals of the Rheumatic Diseases
|
January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
The New England Journal of Medicine
|
December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Rheumatology and Therapy
|
October 7, 2021
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Irene van der Horst-Bruinsma, Corinne Miceli-Richard, Juergen Braun, et al.
Rheumatology and Therapy
|
December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Dermatology and Therapy
|
March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Medical Care
|
December 28, 2012
Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration
Li Wang, Brian Porter, Charles Maynard, et al.
RMD Open
|
December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Jürgen Braun, Atul Deodhar, Robert Landewé, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 9, 2016
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
Atul A Deodhar, Maxime Dougados, Dominique L Baeten, et al.
European Journal of Rheumatology
|
November 3, 2018
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
Walter P Maksymowych, Vibeke Strand, Peter Nash, et al.
Arthritis Care & Research
|
November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
Tore K Kvien, Philip G Conaghan, Laure Gossec, et al.
Annals of the Rheumatic Diseases
|
January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
The New England Journal of Medicine
|
December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Rheumatology and Therapy
|
October 7, 2021
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Irene van der Horst-Bruinsma, Corinne Miceli-Richard, Juergen Braun, et al.
Rheumatology and Therapy
|
December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Dermatology and Therapy
|
March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Medical Care
|
December 28, 2012
Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration
Li Wang, Brian Porter, Charles Maynard, et al.
RMD Open
|
December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Jürgen Braun, Atul Deodhar, Robert Landewé, et al.
Page
of 5